Form 4: Telesis Bio Inc. CEO Todd Robert Nelson Reports Changes in Beneficial Ownership

CEO Todd Robert Nelson reports transactions involving Telesis Bio Inc. stock, including acquisition of restricted stock units and shares withheld for tax obligations.

Summary

• Todd Robert Nelson, CEO of Telesis Bio Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On June 22, 2023, Nelson acquired 47,700 shares of common stock as restricted stock units (RSUs) at $0.
• On March 1, 2024, 4,756 shares were disposed of at $0.528 to cover tax withholding obligations related to RSU vesting.
• As of the report, Nelson directly owns 174,240 shares of common stock.
• Nelson also indirectly owns 6,000,000 shares through GATTACA Mining LLC and 122,516 shares through M-185 Corporation.
• Nelson was granted an option to buy 385,500 shares of common stock at an exercise price of $1.66 on June 22, 2023, which vests over time.
• 25% of the shares subject to the option vested on March 1, 2024, and 1/36th of the remaining shares vest monthly thereafter.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, which are generally viewed neutrally to positively as they align management interests with shareholders. There are no alarming or negative indicators.

Positives

• The granting of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule of the RSUs and stock options incentivizes the CEO to remain with the company.

Negatives

• The disposal of shares to cover tax obligations, while standard, slightly reduces the CEO's direct holdings.

Risks

• The value of the stock options is dependent on the future performance of Telesis Bio Inc.
• The CEO's indirect ownership through GATTACA Mining LLC and M-185 Corporation could present potential conflicts of interest.

Future Outlook

The vesting schedule of the RSUs and stock options extends to March 1, 2027, and beyond, suggesting a long-term commitment from the CEO.

Industry Context

Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices for CEOs in the biotechnology industry, aligning their interests with shareholder value creation.
• Vesting schedules are typically structured to incentivize long-term performance and retention, similar to practices at companies like Illumina or Thermo Fisher Scientific.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders due to the change in the CEO's holdings.
• Employees may be indirectly affected by the CEO's incentivized performance.

Key Dates

Keywords

Telesis Bio Inc., Todd Robert Nelson, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, GATTACA Mining LLC, M-185 Corporation